Table 4.
Figure of merit (95% CI) | P-value | ||||
---|---|---|---|---|---|
Standard group iDose (A) |
RPP group 50 keV (B) |
RPP group DL-iodine boosting (C) |
(A) vs. (B) | (A) vs. (C) | |
Arterial phase | |||||
All FLLs (n = 62) | 0.594 (0.468, 0.721) | 0.825 (0.713, 0.936) | 0.742 (0.574, 0.911) | 0.006 | 0.163 |
< 20 mm (n = 50) | 0.574 (0.438, 0.711) | 0.735 (0.569, 0.901) | 0.632 (0.506, 0.758) | 0.059 | 0.524 |
Portal venous phase | |||||
All FLLs (n = 62) | 0.606 (0.476, 0.735) | 0.800 (0.675, 0.925) | 0.747 (0.563, 0.931) | 0.033 | 0.216 |
< 20 mm (n = 50) | 0.577 (0.452, 0.702) | 0.698 (0.596, 0.800) | 0.620 (0.491, 0.749) | 0.086 | 0.624 |
Note: CI = confidence interval, FLLs = focal liver lesions, RPP = renal protection protocol. Figure of merit was not calculated for FLLs ≥ 20 mm due to the small number of FLLs (n = 12). P-value < 0.017 indicated a significant difference